IL-6 blockade in the management of non-infectious uveitis

Clinical Rheumatology
Giuseppe LopalcoLuca Cantarini

Abstract

Several pathogenetic studies have paved the way for a newer more rational therapeutic approach to non-infectious uveitis, and treatment of different forms of immune-driven uveitis has drastically evolved in recent years after the advent of biotechnological drugs. Tumor necrosis factor-α targeted therapies, the first-line recommended biologics in uveitis, have certainly led to remarkable results in patients with non-infectious uveitis. Nevertheless, the decision-making process turns out to be extremely difficult in anti-tumor necrosis factor or multidrug-resistant cases. Interleukin (IL)-6 holds a critical role in the pathogenic pathways of uveitis, due to its extended and protean range of effects. On this background, manipulation of IL-6 inflammatory cascade has unraveled encouraging outcomes. For instance, rising evidence has been achieved regarding the successful use of tocilizumab, the humanized monoclonal antibody targeted against the IL-6 receptor, in treating uveitis related to juvenile idiopathic arthritis or Behçet's disease. Similar findings have also been reported for uveitis associated with systemic disorders, such as rheumatoid arthritis or multicentric Castleman disease, but also for idiopathic uveitis, the rare bi...Continue Reading

Associated Clinical Trials

References

Apr 1, 1996·The British Journal of Ophthalmology·A RothovaA Kijlstra
Dec 20, 2000·European Journal of Biochemistry·T JostockS Rose-John
Jul 11, 2003·Ocular Immunology and Inflammation·Aniki Rothova
Jul 13, 2005·Archives of Ophthalmology·Eric B SuhlerJames T Rosenbaum
Aug 1, 2006·Ophthalmology·Charlotte W T A LardenoyeAniki Rothova
Oct 2, 2007·Arthritis and Rheumatism·Lyndell L LimJames T Rosenbaum
Jan 24, 2009·Rheumatology·Takeru YoshimuraAkihiko Yoshimura
May 9, 2009·Rheumatology·Claire Immediato DaïenUNKNOWN Club Rhumatismes et Inflammation (CRI)
Jun 29, 2010·European Journal of Immunology·Akihiro Kimura, Tadamitsu Kishimoto
Dec 15, 2010·European Journal of Cell Biology·Athena ChalarisJürgen Scheller
Jan 11, 2011·Korean journal of pediatrics·Ki Hwan Kim, Dong Soo Kim
Feb 22, 2011·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Ahmed M Abu El-AsrarJo Van Damme
May 17, 2011·American Journal of Ophthalmology·Jonas J W KuiperAniki Rothova
Oct 6, 2011·Ocular Immunology and Inflammation·Aurore MuselierAlain Bron
Nov 15, 2011·Clinical Neurology and Neurosurgery·Lee S ShapiroAfshin Borhani Haghighi
Nov 29, 2011·Survey of Ophthalmology·Khayyam DurraniC Stephen Foster
Feb 14, 2012·Ocular Immunology and Inflammation·Joseph N MartelNisha R Acharya
Feb 14, 2012·Expert Opinion on Therapeutic Targets·Georg H Waetzig, Stefan Rose-John
Jun 5, 2012·The Journal of Rheumatology·Christoph TappeinerArnd Heiligenhaus
Dec 29, 2012·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Alfredo AdánLaura Pelegrín
Apr 6, 2013·Rheumatology·Andreas P Diamantopoulos, Gulen Hatemi
Apr 11, 2013·Immunologic Research·Francesco CasoAndrea Doria
Jul 31, 2013·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Alfredo AdánLaura Pelegrín
Sep 26, 2013·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Alfredo AdánConsuelo Modesto
Jan 15, 2014·Seminars in Immunology·Jeffrey J BabonNicos A Nicola
Feb 18, 2014·Clinical Ophthalmology·Tomohito SatoMasaru Takeuchi
Mar 20, 2014·Dermatology : International Journal for Clinical and Investigative Dermatology·Antonio VitaleLuca Cantarini
Apr 16, 2014·Clinical Rheumatology·Luca CantariniFlorenzo Iannone
Aug 2, 2014·Clinical Reviews in Allergy & Immunology·Ivan Foeldvari
Sep 6, 2014·Cold Spring Harbor Perspectives in Biology·Toshio TanakaTadamitsu Kishimoto
Sep 11, 2014·Ophthalmology·Marina MesquidaAlfredo Adán
Sep 15, 2014·Current Rheumatology Reports·Yongdong Zhao, Carol Wallace
Oct 18, 2014·Expert Opinion on Drug Safety·Miguel Cordero-ComaTaygan Yilmaz

❮ Previous
Next ❯

Citations

Nov 18, 2017·Ocular Immunology and Inflammation·Emmett T CunninghamManfred Zierhut
Mar 20, 2019·Expert Opinion on Biological Therapy·Sara TouhamiDavid Saadoun
Jul 24, 2020·Expert Review of Clinical Immunology·Carla GaggianoClaudia Fabiani
Sep 5, 2020·Expert Opinion on Drug Safety·Giuseppe LopalcoFlorenzo Iannone
Jun 9, 2020·Frontiers in Pharmacology·Rodrigo A ValenzuelaCristhian A Urzua
Nov 1, 2020·Neurology. Neuroimmunology and Neuroinflammation·Alan AbrahamDenize Atan
Nov 5, 2020·Expert Opinion on Emerging Drugs·Ilknur Tugal-Tutkun, Pinar Çakar Özdal
Jan 13, 2021·Ocular Immunology and Inflammation·Emmett T CunninghamManfred Zierhut
Nov 17, 2020·Frontiers in Immunology·Sandro F PerazzioAlexandre W S de Souza
Jun 12, 2020·Seminars in Arthritis and Rheumatism·Florence A AeschlimannBrigitte Bader-Meunier

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bioinformatics in Biomedicine

Bioinformatics in biomedicine incorporates computer science, biology, chemistry, medicine, mathematics and statistics. Discover the latest research on bioinformatics in biomedicine here.

Castleman Disease

Castleman disease is a rare disorder that involves an overgrowth of cells in the lymph nodes. Unicentric Castleman disease affects one lymph node, usually in the chest or abdomen. Multicentric Castleman disease affects multiple lymph nodes, commonly located in the neck, collarbone, underarm and groin areas. Discover the latest research on Castleman disease here.